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Abstract
Background: Detection of cytologic atypia in nipple aspirate fluid (NAF) has been shown to be a
predictor of risk for development of breast carcinoma. Manual collection of NAF for cytologic
evaluation varies widely in terms of efficacy, ease of use, and patient acceptance. We investigated
a new automated device for the non-invasive collection of NAF in the office setting.
Methods: A multi-center prospective observational clinical trial involving asymptomatic women
designed to assess fluid production, adequacy, safety and patient acceptance of the HALO NAF
Collection System (NeoMatrix, Irvine, CA). Cytologic evaluation of all NAF samples was
performed using previously described classification categories.
Results: 500 healthy women were successfully enrolled. Thirty-eight percent (190/500) produced
fluid and 187 were available for cytologic analysis. Cytologic classification of fluid producers showed
50% (93/187) Category 0 (insufficient cellular material), 38% (71/187) Category I (benign non-
hyperplastic ductal epithelial cells), 10% (18/187) Category II (benign hyperplastic ductal epithelial
cells), 3% (5/187) Category III (atypical ductal epithelial cells) and none were Category IV
(unequivocal malignancy). Overall, 19% of the subjects produced NAF with adequate cellularity and
1% were found to have cytologic atypia.
Conclusion: The HALO system is a simple, safe, rapid, automated method for standardized
collection of NAF which is acceptable to patients. Cytologic assessment of HALO-collected NAF
showed the ability to detect benign and pre-neoplastic ductal epithelial cells from asymptomatic
volunteers.
Background
The majority of breast cancers originate in the epithelium
lining the milk ducts. It is believed that most breast can-
cers are slow growing and progress from precancerous
cells, which have cellular and nuclear changes that can be
identified microscopically. Finding microscopic evidence
of ductal epithelial atypia/atypical ductal hyperplasia
(ADH) has been shown in previous epidemiologic studies
to be a predictor of future breast cancer development in an
individual woman. [1-10] This increased risk has been
identified using random peri-areolar fine needle aspira-
tion (FNA), tissue biopsy or nipple secretion samples for
assessment of cytologic atypia.
Published: 03 August 2005
BMC Women's Health 2005, 5:10 doi:10.1186/1472-6874-5-10
Received: 28 February 2005
Accepted: 03 August 2005
This article is available from: http://www.biomedcentral.com/1472-6874/5/10
© 2005 Proctor et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Women's Health 2005, 5:10 http://www.biomedcentral.com/1472-6874/5/10
Page 2 of 14
(page number not for citation purposes)
Nipple fluid or secretions, usually aspirated from the
breast ducts, is a protein rich material termed nipple aspi-
rate fluid (NAF) which can be microscopically examined
for the presence of atypical ductal epithelial cells. Nipple
fluid can be obtained from many women, with reports of
NAF production ranging from 25% [11] to more than
95% [12] of women. There are a variety of factors associ-
ated with the ability to produce nipple fluid, particularly
intrinsic breast characteristics [13]. Nipple fluid acquisi-
tion methods are various, including manual breast com-
pression, either followed by manual breast pump or
syringe-type device with suction, sometimes repeated up
to 10 minutes on each breast.
Breast cancer risk assessment using breast fluid cytology
has been suggested to have a role in risk stratification and
clinical decision making for women who are at high risk
for breast cancer development. Ductal lavage is for clinical
use in high-risk women and involves identification and
cannulation of one or more fluid-yielding duct(s) then
rinsing each with saline, collecting and analyzing the lav-
aged fluid. The finding of atypical cells could potentially
influence a woman's decision for more aggressive surveil-
lance or chemoprevention. Women with atypical ductal
hyperplasia in the Breast Cancer Prevention Trial showed
an 86% risk reduction with tamoxifen chemoprevention
[14].
We analyzed cytologic features of samples obtained dur-
ing a pilot study using a new suction-based automated
mechanical device for the non-invasive collection of NAF
in the office setting. This article reports the results from a
multi-center prospective observational clinical trial
involving asymptomatic women designed to evaluate
fluid production, adequacy, safety, patient acceptance and
ability to detect atypical breast epithelial cells.
Methods
Study sponsor and study design
The study sponsor was Neomatrix, LLC (Irvine, Ca). The
study design and execution was the responsibility of the
study sponsor. The author's institution (ARUP Laborato-
ries) provided contracted pathology services for the study
sponsor, on a usual and customary fee-for-service basis.
Study administration expenses at the parent institution
(University of Utah) were paid by the study sponsor. No
direct compensation was made to the manuscript authors.
The study was conducted over a one year period and no
preparatory phase was incorporated. The participant
enrollment sites were obstetric and gynecology clinic prac-
tices located in Avon, CT., Farmington, CT., and Baton
Rouge, LA. There was a single set-up instructional visit that
took less than one hour and was performed prior to initi-
ation of the investigation. The only variation in collection
rates was seen between centers. One site had a lower NAF
collection rate initially. The HALO System at this site was
evaluated and the equipment was found to be operating
outside of its specified performance parameters. The
equipment was replaced and the variability in NAF collec-
tion rates between centers was no longer observed. During
the study, enrollment was stopped for approximately 6
months in order to make some minor design modifica-
tions to enhance equipment performance.
Patient enrollment
The study population included only asymptomatic, non-
pregnant, non-lactating women with no history of breast
cancer, breast surgery (e.g. breast augmentation or breast
reduction), or nipple piercing who were asked to volun-
teer as part of a prospective multi-center observational
study.
Participants were required to be at least 18 years old and
there was no upper age limit. Written informed consent
was obtained from all subjects before enrollment in the
study. The study protocol was approved for all participat-
ing collection centers by Biomedical Research Institute of
America (San Diego, CA), an independent Institutional
Review Board (Protocol PP-01) and the University of Utah
(IRB #11588) Institutional Review Board. All rules and
regulations concerning biomedical studies with human
subjects were followed. A standardized questionnaire was
completed for all participants that included medical his-
tory, current medications, family history, obstetric and
gynecologic history, and breast health history including
any previous biopsies and mammogram results. Gail
model 5-year risk profiles were calculated for each woman
over the age of 35 http://bcra.nci.nih.gov/brc.
Nipple aspiration procedure
After obtaining written informed consent and completing
a study questionnaire, a clinical breast exam was per-
formed. The subject was wearing a front-opening exami-
nation gown and seated in a comfortable position. Each
breast was cleaned using an alcohol wipe. Abrasive
cleanser was not used. The HALO NAF Collection System
(NeoMatrix, Irvine, CA) (Fig 1) has adjustable breast cups
with disposable sample collection cups which were placed
simultaneously on each breast and manually adjusted to
fit snugly around the nipple and areola. The application of
topical anesthetic was not required. Occasionally, some
breast tissue proximal to the areola was covered by the
petals depending on the breast size. After both breast cups
are secure, the START button is depressed to initiate the
automatic NAF acquisition cycle (Fig. 2). The HALO con-
sole initiates the vacuum, providing a gentle suction (sim-
ilar to that of a breast pump) on both breasts.
Simultaneously with suction, heat is applied to the cov-
ered areas via circulating warm fluid within the Breast CupBMC Women's Health 2005, 5:10 http://www.biomedcentral.com/1472-6874/5/10
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petals. Towards the end of the cycle, the HALO system ini-
tiates mild compression of the Breast Cup petals to
retrieve any fluid from the ducts. The entire cycle is 5 min-
utes in duration. The Console indicates when the NAF
acquisition cycle has completed. Suction is gently auto-
matically released from the breast cups.
Any collected NAF was transferred from the nipple or
sample collection cup(s) to a vial of fixative (CytoLyt,
Cytyc Corporation, Boxborough, MA) using a pipette if
necessary. If fluid was obtained from either one or both
breasts, all samples were combined into a single sample
preservative vial. Only one attempt was made to obtain
NAF in the five minute session, and if no NAF was pro-
duced by either breast, the participant was considered to
be a non-producer.
Sample processing and cytologic examination
All samples were shipped to a single reference laboratory
(ARUP Laboratories, Inc., Salt Lake City, UT). Microscopic
slides were prepared from the entire NAF sample using a
Millipore filter technique (Millipore Corp., Billerica, MA),
which was chosen due to the low cellularity of the speci-
mens. The filter preps were stained with the modified
Papanicolaou stain technique.
Each slide was reviewed by one of a group of three
cytopathologists with experience examining breast
The HALO NAF collection system (photos courtesy of NeoMatrix, Irvine, CA) Figure 1
The HALO NAF collection system (photos courtesy of NeoMatrix, Irvine, CA). A. Control Console B. Adjustable Breast Cups 
with Fluid Reservoir Cassette C. Disposable Sample Collection Cups.BMC Women's Health 2005, 5:10 http://www.biomedcentral.com/1472-6874/5/10
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cytologic specimens, including ductal lavage, and who
were trained in the NAF cytologic categories prior to
beginning the study. All difficult or borderline cases were
resolved by reviewing cases at a multi-headed microscope.
The slides were classified according to the most severe
abnormality detected using one of five categories based
upon increasing nuclear abnormality. The classification
system used categories developed by King et al (Table 1).
Category 0 was designated for unsatisfactory specimens,
with insufficient material for complete evaluation,
defined microscopically as having less than 10 ductal epi-
thelial cells. Category I samples contained benign non-
hyperplastic ductal epithelial cells. Category II was
defined as ductal epithelial hyperplasia with cellular
arrangements of cohesive clusters (greater than 10 – 50
cells) and minimal cellular changes including mild
nuclear and cellular enlargement and occasional nucleoli
but finely granular and evenly distributed chromatin. Cat-
egory III, atypical hyperplasia, included cells with more
distinct nuclear enlargement, increased nuclear to cyto-
plasmic ratios, coarsely granular chromatin with promi-
nent chromocenters and irregular nuclear membranes
with nuclear variation. Increased numbers of atypical sin-
gle cells were also included in this group. Category IV was
defined as unequivocally malignant cells.
Data collection and monitoring
Enrollment site investigators and study coordinators filled
out case report forms recording relevant information
about the subjects' medical history, eligibility, study pro-
cedures, adverse events, and any available follow-up care.
All clinical sites were monitored and all study data,
including final cytology results, where collected by the
study sponsor, NeoMatrix.
Patient acceptance and post-procedure survey
Adverse events were noted immediately after the proce-
dure as well as at the four to eight week post-procedure
survey. The participant was asked to rate her comfort level
immediately following the procedure using a visual ana-
log scale of 1 to 10, with one being most comfortable and
10 being least comfortable. Participants were also con-
tacted four to eight weeks after the procedure to assess sat-
isfaction with the procedure. Women with cytologic
atypia or worse (Class III or IV) were referred to their reg-
ular physicians who determined the appropriate follow-
up care. A standard protocol for following patients with
atypia was not included as part of this investigation. This
follow-up care may have included further assessment of
the patient via imaging, biopsy in some cases, risk coun-
seling, and increased surveillance.
Statistical analysis
The result of NAF producers and non-producers were
expressed as raw numbers for each demographic category.
Comparison between two groups was performed using
the χ2 test of association. The difference between values
was considered significant at P < 0.05.
Results
Enrollment demographics
Five hundred (n = 500) participants were successfully
enrolled. Overall characteristics of the study participants
are summarized in Table 2. The average age was 41.1 years
(range 18–65). There was no significant difference
between age and fluid production (p <= 1.0). One-hun-
dred and ninety (38%) of the women were fluid produc-
ers. Thirty-eight percent (162/426) of women less than 55
years old were fluid producers, while 38% (28/74) of
women aged 55 or older produced fluid. Eighty-nine per-
cent (445/500) were Caucasian, 9% (47/500) were Afri-
can American, 1% (7/500) were Hispanic and one
participant was Asian. Forty-eight percent of nulliparous
women were fluid producers whereas 36% of parous
women produced NAF, which is not statistically signifi-
cant for the group of pre-menopausal women (p <= 1.0),
but is significant if all women are included (p < 0.05).
Thirty-nine percent of Caucasians produced NAF while
The HALO device applied to a breast Figure 2
The HALO device applied to a breast. (Photos courtesy of 
NeoMatrix, Irvine, CA.) An alcohol wipe is used to cleanse 
the nipples (step 1); cups are placed on the woman's breasts 
and adjusted to fit (step 2); heat and suction are simultane-
ously applied via the breast cup petals (step 3); mild com-
pression is initiated by the console (step 4); any sample of 
NAF obtained is transferred to a vial of cytology fixative and 
transported to the cytology lab (step 5).BMC Women's Health 2005, 5:10 http://www.biomedcentral.com/1472-6874/5/10
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NAF was obtained from 31% of non-white subjects (p <=
1.0). Thirty-six percent of subjects with no 1st degree fam-
ily history produced NAF, 46% of subjects with one 1st
degree relative with breast cancer, and 75% of subjects
who had more than one 1st degree relative with breast can-
cer (p <= 0.10). Forty-two percent of women with a lacta-
tion history produced NAF while 34% of women who
never lactated were fluid producers (p < 0.10). Overall,
14% had at least one first degree relative with cancer and
11% had a history of a previous breast biopsy. In sum-
mary, none of the differences between fluid producers and
non-producers with regards to any of the listed demo-
graphics was statistically significant.
Nipple aspirate fluid analysis
Three of the 190 specimens collected from the fluid pro-
ducers had a container leak during specimen transport
and therefore could not be analyzed, with the remaining
187 available for evaluation. The final cytology results are
summarized in Table 3. Fifty percent (93/187) of the NAF
samples were classified as Category 0, 38% (71/187) Cat-
egory I (Figure 3), 10% (18/187) Category II (Figure 4),
and 3% (5/187) Category III (Figures 5 and 6). No Cate-
gory IV (unequivocal malignancy) samples were identi-
fied. Statistical analysis whereby all patients 55+ are
combined into one group in order to strengthen the raw
numbers showed there was no significant difference
between age groups or cytologic categories (p = 0.27).
Procedure acceptance and adverse events
A total of 419/500 (84%) women were surveyed for pro-
cedure acceptance four to eight weeks after their
procedure. The average comfort assessment rating imme-
diate post-procedure was 5.0 on a scale of 1–10 (one
being most comfortable) and 4.2 at the four to eight week
telephone/mail post-procedure survey (Table 4). The nip-
ple, areola, and breast areas were visually assessed by the
study nurse immediately following the procedure.
Twenty-six percent of the participants had no observed
skin redness after the procedure, 59% mild redness, 14%
moderate redness and less than one per cent had severe
redness reported. No major adverse events were reported.
Two participants chose to discontinue the procedure mid-
cycle due to discomfort and there were five reported
minor events including bleeding or small surface lacera-
tions. These were treated with topical ointment, observa-
tion, Keflex for one suspected mild mastitis, and Mycolog
for candiasis noted in one participant. All resolved with-
out further intervention. Eighty-three percent of the par-
ticipants reported that they would have the HALO
procedure again and 88% said they would recommend
the procedure to others.
Nipple aspirate fluid and Gail score
Gail 5 year risk profiles were obtained for the participants
over the age of 35. Overall, no statistical difference was
seen with regards to fluid production and calculated Gail
profile result (p = 0.2). Comparison of Gail risk (>1.7%
vs. <1.7%) and cytology category results, for the 190
Table 1: Nipple aspirate fluid cytology classification*
Classification Characteristics Interpretation
Unsatisfactory (Category 0) <10 ductal epithelial cells. Unsatisfactory specimen.
Benign (Category I) Duct epithelial cells within normal limits. Foam 
cells. Apocrine metaplastic cells.
No malignant cells identified. Benign (non-
hyperplastic) ductal epithelial cells present.
Hyperplasia (Category II) Minimal changes including slight cell and nuclear 
enlargement. Chromatin remains finely granular 
and evenly distributed. Small and regular 
nucleoli sometimes present. Cell distribution 
predominately in groups and cohesive with 
>10–50 cells (papillary and apocrine 
subcategories).
No malignant cells identified. Benign 
hyperplastic ductal epithelial cells present.
Atypical Hyperplasia (Category III) Moderate to severe abnormalities with distinct 
nuclear enlargement, increasing nuclear to 
cytoplasmic ratio, irregular nuclear borders, 
and nuclear variation. Coarsely granular 
chromatin. Prominent chromocenters. Cell 
distribution in groups with some papillary 
formations. Increased numbers of single 
atypical cells (apocrine type subcategory).
Atypical hyperplastic ductal epithelial cells 
present. Malignancy cannot be completely 
excluded.
Malignancy (Category IV) Single cells and groups of cells with unequivocal 
nuclear features of cancer.
Malignant cells present derived from 
adenocarcinoma.
* King et al [4]BMC Women's Health 2005, 5:10 http://www.biomedcentral.com/1472-6874/5/10
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Table 2: Participant characteristics, demographics and fluid production status
Overall, No. (%) NAF Producers, No. (% of subgroup) p-value
Total No. of Women Enrolled 500 190 (38.0)
Age groups, y, No. (%) p <= 1.0
18–24 63 (12.6) 16 (25.4)
25–34 93 (18.6) 36 (38.7)
35–44 115 (23.0) 45 (39.1)
45–54 155 (31.0) 65 (41.9)
55–64 71 (14.2) 26 (36.6)
65+ 3 (0.6) 2 (66.7)
Parity, No. (%) p <= 0.05 ***
Nulliparous 83 (16.6) 40 (48.2)
Parous 417 (83.4) 150 (36.0)
Age at Menarche, years, No. (%) p <= 1.0
<=12 241 (48.2) 90 (37.3)
13–14 193 (38.6) 77 (39.9)
>=15 61 (12.2) 21 (34.4)
Missing 5 (1.0) 2 (40)
Ethnicity, No. (%) p <= 1.0
Caucasian 445 (89.0) 173 (38.9)
Non-Caucasian* 55 (11.0) 17 (30.9)
1st Degree Relatives with breast cancer, No. (%) p <= 0.1
No 429 (85.8) 156 (36.4)
Yes, 1 67 (13.4) 31 (46.3)
Yes, >=2 4 (0.8) 3 (75.0)
History of breast biopsy, No. (%) p <= 1.0
Yes** 56 (11.2) 22 (39.3)
Menstrual status, No. (%) p <= 1.0
Pre-Menopausal 358 (71.6) 137 (38.3)
Menopausal 142 (28.4) 53 (37.3)
Lactation history, No. (%) p <= 0.1
Never lactated 268 (53.6) 92 (48.4)
History of lactation 232 (46.4) 98 (51.6)
* 47 total African American, 1 Asian, and 7 Hispanic. **type of biopsy not reported *** If only pre-menopausal women are included in the analysis 
of NAF production vs. parity there is no significant difference (p <= 1.0)
Table 3: Nipple aspirate fluid (NAF) cytologic findings
Cytologic 
diagnosis
No. of women/
Total No. fluid 
producers (%)
18–24 yr, No. 
(%)
25–34 yr, No. 
(%)
35–44 yr, No. 
(%)
45–54 yr, No. 
(%)
55–64, No. (%) 65 + yrs, No. 
(%)
Unsatisfactory 
(Category 0)
93/187 (49.7) 9/93 (9.7) 14/93 (15.1) 22/93 (23.7) 32/93 (34.4) 15/93 (16.1) 1/93 (1.1)
Benign 
(Category I)
71/187 (38.0) 5/71 (7.0) 15/71 (21.1) 21/71 (29.6) 25/71 (35.2) 5/71 (7.0) 0
Hyperplasia 
(Category II)
18/187 (9.6) 1/18 (5.6) 6/18 (33.3) 1/18 (5.6) 5/18 (27.8) 5/18 (27.8) 0
Atypical 
Hyperplasia 
(Category III)
5/187 (2.8) 1/5 (20.0) 0 1/5 (20.0) 2/5 (40.0) 0 1/5 (20.0)
Malignancy 
(Category IV)
0 / 1 8 7  ( 0 . 0 ) 000000
S a m p l e  L e a k 3 / 1 8 7  ( 1 . 6 ) 010110BMC Women's Health 2005, 5:10 http://www.biomedcentral.com/1472-6874/5/10
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A-B. Category I. Benign (non-hyperplastic) ductal epithelial cells Figure 3
A-B. Category I. Benign (non-hyperplastic) ductal epithelial cells. The breast ductal epithelial cells are single, small, and uniform 
(arrow-A). Foam cells are a frequent finding (arrow-B). Apocrine metaplastic cells are sometimes identified. Pap 100X.BMC Women's Health 2005, 5:10 http://www.biomedcentral.com/1472-6874/5/10
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women assessed, showed no significant difference (p =
0.68).
Post-procedure monitoring
The five women found to have Category III changes were
referred for further breast care by their regular physicians.
One of these women initially had a benign breast biopsy
but was subsequently noted to have ductal carcinoma in
situ (DCIS) on a follow-up repeat breast biopsy six
months later done as part of an increased surveillance
plan as determined by her physician. A second woman
had negative bilateral biopsies and the third woman with
surgical follow-up had a biopsy that showed lobular car-
cinoma in situ (LCIS). One of the five Category III women
had negative follow-up ultrasound imaging and is being
closely followed with mammography every six months.
The last of the Category III women, a 24-year-old Cauca-
sian woman with a strong family history of breast cancer
in her mother, maternal grandmother and aunt (all diag-
nosed premenopausally), had negative initial imaging but
was subsequently found to have a lump by clinical breast
exam. Follow-up ultrasound imaging was again negative.
It was recommended that this woman undergo genetic
counseling. Follow-up information was not obtained for
the Category 0, I or II women and further follow-up of the
Category III subjects was not part of this protocol. The
Category III women are being followed as high-risk indi-
viduals per their physicians' standard protocol outside of
this investigation. Only one of these Category III women
was identified as being high-risk prior to the NAF collec-
tion, using the Gail risk profile calculated at enrollment.
Discussion
Many studies have shown that finding atypical hyperpla-
sia of the breast ductal epithelium is associated with an
increased risk of subsequent development of breast cancer
[1-7]. Wrensch and colleagues have observed in a prospec-
tive trial that NAF production and NAF atypia in a
screening population are associated with an increased risk
of breast cancer. Further, cytologic assessment of NAF may
modestly improve the discriminatory accuracy of the Gail
risk model in a screening population [10]. However, NAF
collection requires time and experienced trained person-
nel. We report prospective cytologic examination of NAF
collected from otherwise asymptomatic healthy women
obtained in a pilot study using the automated HALO Sys-
tem. We found that it is technically feasible to detect nor-
mal and atypical breast ductal epithelial cells using
A-B. Category II. Benign hyperplasia Figure 4
A-B. Category II. Benign hyperplasia. The cells are distributed mainly in cohesive groups of 10–50 cells. Minimal cytologic 
changes are seen including slight cell and nuclear enlargement. The nuclear chromatin is finely granular and evenly distributed 
and small regular nucleoli are sometimes present. Pap 100X.BMC Women's Health 2005, 5:10 http://www.biomedcentral.com/1472-6874/5/10
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routine cytologic preparation methods and a modified
classification system, adapted from King et al [4]. Thirty-
eight percent of participants produced a NAF sample and
of the samples obtained, 50% had adequate ductal epithe-
lial cells for cytology analysis and five asymptomatic
women (5/500, 1%) had Category III changes (atypical
hyperplasia). Compared to other studies reporting non-
invasive NAF collection (Table 5), the percentage of par-
ticipants who produced fluid using the HALO collection
system falls into the range of these previous manual meth-
A-D. Category III. Atypical hyperplasia Figure 5
A-D. Category III. Atypical hyperplasia. NAF from a 65-year-old Caucasian woman with a family history of breast cancer and an 
elevated Gail index of 3.0%. NAF analysis reveals moderate to severe cytologic abnormalities including distinct nuclear enlarge-
ment, increasing nuclear to cytoplasmic ratio, irregular nuclear borders, and nuclear variation. The chromatin is coarsely gran-
ular and there are prominent chromocenters. While the cells are distributed mainly in groups with occasional papillary 
formations, there are also increased numbers of single atypical cells (arrow-A). After the Category III findings, a ductal biopsy 
was performed that was found to be benign. A breast biopsy six months later showed DCIS. Pap 100X.BMC Women's Health 2005, 5:10 http://www.biomedcentral.com/1472-6874/5/10
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ods (18%–74%). We observed that 19% of the partici-
pants had adequate cellularity (defined in this study as
greater than 10 ductal epithelial cells present) which is
similar to the few studies that recorded cytology results,
although there is wide variability (18%–71%).
Overall, the HALO NAF collection procedure was found
to be acceptable by the women studied, rapid, and posed
little physical risk. This device has an advantage over other
methods of NAF collection in that it is automatic and easy
to use, thereby removing most clinician variability. It is
A-D. Category III. Atypical hyperplasia Figure 6
A-D. Category III. Atypical hyperplasia. NAF from a 45-year-old Caucasian woman with a Gail index of 1.1% and no significant 
medical history. NAF analysis reveals moderate to severe cytologic abnormalities including distinct nuclear enlargement, 
increasing nuclear to cytoplasmic ratio, irregular nuclear borders, and nuclear variation. The chromatin is coarsely granular and 
there are prominent chromocenters. Follow-up bilateral biopsies showed LCIS in the right breast, and hyperplastic changes in 
the left. The changes depicted in these micrographs are not specific for either of those entities and may have originated from 
other areas of atypia (e.g., DCIS) that was not sampled by the biopsies. Pap 100X.BMC Women's Health 2005, 5:10 http://www.biomedcentral.com/1472-6874/5/10
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Table 4: Patient acceptance and adverse events
Initial (n = 500) Post-procedure survey (n = 419)
HALO comfort assessment (scale 0–10) 5.0 4.2
Redness post HALO No. (%) No. (%)
None 130 (26.0) 0
Mild 297 (59.4) 0
Moderate 71 (14.2) 0
Severe 2 (0.4) 0
Would recommend HALO to others N/A 367 (87.6)
Would choose HALO again N/A 349 (83.3)
Table 5: Comparison of non-invasive NAF collection by series
Series Subject Population Fluid Acquisition 
Method
% Fluid Obtained % samples with >10 
ductal epithelial cells 
present for cytologic 
assessment
Papanicolaou et al 1958 [2] n = 917 asymptomatic 
women; 19–75 yrs
Manual compression 
followed by manual breast 
pump
18% Specimen cellularity not 
specifically reported; ~50% 
of samples "sparsely 
cellular with no evidence of 
atypia"
Petrakis et al 1975 [15] n = 606 healthy volunteers; 
>18 yrs; Caucasian, Filipina, 
African American, Mexican, 
Asian
Manual compression & 
suction
48% Findings reported as 
secretor or non-secretor; 
cellularity not reported
Sartorius 1977 [3] n = 203 without breast 
disease; n = 1503 patients 
with positive or suspect 
breast disease
Sartorius syringe – device; 
manual compression & 
suction
65% (age 31–50); 30–40% 
(age <20/>60)
48% of 203 without 
disease; 54% of women 
with known or suspected 
breast disease
Buehring 1979 [16] n = 1744 self-selected; 
mostly asymptomatic 
volunteers; >18 yrs; 
Caucasian
Sartorius method 49% 36% NAF samples; 18% 
overall "satisfactory"
Petrakis et al 1981 [17] n = 3929 volunteers from 
health fairs; >=18 yrs; 
Caucasian
Sartorius method 56% Findings reported as 
secretor or non-secretor; 
cellularity not reported
Wynder et al 1981 [18] n = 244 Finnish volunteers; 
age 20–69
Sartorius method; repeated 
up to 10 min
38% Cytology not assessed
Wynder et al 1985 [19] n = 990 volunteers; age 
30–70 (289 "healthy"'; 548 
with benign breast disease; 
153 with untreated breast 
cancer)
Sartorius method; repeated 
up to 10 min
38–57% Cytology not assessed
Wrensch et al 1990 [13] n = 1428 with no history of 
breast cancer; age 20–74
Sartorius method 37% Findings reported as 
secretor or non-secretor; 
cellularity not reported
Wrensch et al 1992 [8] n = 2701 Caucasian 
volunteers; free from 
breast cancer
Sartorius method 74% 87% NAF samples; 71% 
overall fluid with 
satisfactory cytology
Sauter et al 1997 [12] n = 177 non-Asian subjects 
including women with 
history of breast cancer, 
precancerous mastopathy 
and invasive cancer
Modified breast pump 
consisting of syringe 
attached to endotracheal 
tube and respiratory 
humidification adapter
94–99% 96% NAF samples; 53% 
sufficiently cellular for 
DNA analysis
HALO Series 2004 n = 500 healthy volunteers; 
ages 18–65 yrs; 
asymptomatic, no breast 
cancer history
Automated five minute 
cycle (heat, suction, 
compression)
38% 50% NAF samples; 19% 
overall produced samples 
with >10 ductal epithelial 
cellsBMC Women's Health 2005, 5:10 http://www.biomedcentral.com/1472-6874/5/10
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also less invasive than other methods of sampling breast
epithelium in asymptomatic women, such as ductal lav-
age and fine needle aspiration.
Criticisms of using NAF to detect cellular abnormalities
include the observation that fewer adequately cellular
specimens are obtained than with ductal lavage. Dooley et
al compared NAF and DL specimens [20] and found that
on average a larger number of breast ductal epithelial cells
were obtained with DL (13,500) versus nipple aspiration
(120) leading to a greater percentage of adequately cellu-
lar specimens obtained with DL versus nipple fluid
aspiration (78% versus 27% in their study, respectively).
In addition, they found abnormal cytologic findings in a
greater percentage of DL specimens (24%) than in NAF
specimens (9%). In the present study, 38% of the partici-
pants produced fluid with the HALO NAF collection sys-
tem, and of these 50% had specimens that were
adequately cellular giving a 19% overall adequacy rate.
Even though not all women produce NAF, Wrensch et al
[9] showed that women who produce nipple fluid had a
slight (1.5 times) increase in the relative risk of breast can-
cer development and non-producers had a decreased rela-
tive risk compared to all fluid producers regardless of final
diagnosis. One of Papanicolaou's early studies [1]
reported obtaining nipple secretions via breast palpation,
massage or a hand-held breast pump, from approximately
50% of the patient population studied; however, this per-
centage also included women with spontaneous nipple
discharge. Secretions were obtained from approximately
19% of asymptomatic women, with pre-menopausal
women more likely to produce fluid than post-menopau-
sal women in the Papanicolaou study. Sartorius et al [3]
developed a hand held aspiration device, composed of a
syringe attached to a small plastic cup placed over the nip-
ple. Their study obtained fluid from approximately 50%
of the symptomatic women studied. Wrensch et al [8,9]
were able to obtain fluid using a similar device as that
described by Sartorius from 40–80% of the women stud-
ied, with greater percentages obtained in pre-menopausal
women. Krishnamurthy et al [21] obtained fluid from
81% of their study participants; however, these patients
had known cancer diagnoses and were under general
anesthesia. One pilot study has suggested that
administering nasal oxytocin prior to collection can
improve the yield of NAF [22].
Despite these limitations, the ease and convenience of this
method of obtaining breast ductal epithelial cells might
make it a more acceptable option for women who are
undergoing NAF collection. As shown in this study,
participant acceptance of the procedure was adequate
with an average initial comfort assessment rating of 5.0 on
a scale of 1–10. Dooley et al [20] reported a lower pain
rating for nipple aspiration (8 mm on a 100 mm scale
where 0 mm represented "no pain") yet all of the patients
in that study underwent either local or general anesthesia.
Eighty-three percent of the participants in the current
study reported they would have the HALO procedure
again and 88% said they would recommend the proce-
dure to others. Since it can be quickly performed in an
office setting, patients do not need to be referred to a spe-
cialist or scheduled in advance, and can potentially have
the test performed at the time of their annual gynecologic
exam. The procedure is automated to reduce operator var-
iability and can be performed by non-physician staff.
No prospective studies have been done to date that assess
the negative predictive value of ductal cytology in asymp-
tomatic or high risk women. Nipple aspirate fluid
assessment is not a diagnostic test for breast cancer. NAF
production and cytologic assessment may be used in
conjunction with the Gail model for risk prediction and
the automated HALO system may facilitate NAF collec-
tion in the office setting.
While clinical follow-up care of patients with abnormal
breast fluid cytology is not standardized, Shaughnessy et
al [23] published an algorithm for management of high-
risk women who undergo either nipple aspiration or
ductal lavage. Interim management guidelines from the
Breast Cancer Risk Assessment Group (BCRAG) [24] also
emphasized the need for patients with cytologic abnor-
malities to undergo a diagnostic work-up to discover
potential occult lesion.
NAF specimens have important applications in addition
to the cytologic assessments that are described in this
paper. A study by Chagpar et al [25] showed that NAF
specimens could be tested for the presence of the Thom-
sen-Friedenreich (TF) antigen, which has been found to
be elevated in breast carcinoma. They found a significant
difference between healthy breasts and breasts with early-
stage carcinoma, even when measured on NAF samples as
small as 15 µL. Fackler et al [26] recently reported a new
method (quantitative multiplex methylation-specific
PCR) that assesses for promoter hypermethylation of
DNA in breast ductal epithelial cells, even in samples with
as few as 50 cells. This method showed high sensitivity
(84%) and specificity (89%) for four genes seen in breast
carcinomas. Prostate specific antigen levels in NAF have
been shown to decrease with advanced disease stage,
larger tumor size, and nodal involvement in women with
breast cancer [27]. As additional proteomic, biochemical
and genomic biomarkers are identified, testing of NAF
samples may become more commonplace.
Conclusion
The HALO procedure has been shown to be a feasible way
to obtain NAF samples for cytologic assessment and itBMC Women's Health 2005, 5:10 http://www.biomedcentral.com/1472-6874/5/10
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appears to be a safe, rapid, fairly well-tolerated, and non-
invasive procedure. While fluid production and adequacy
rates may not be as high as reported in manual NAF col-
lection series, there may be advantages to using the HALO
System over manual collection techniques. The collection
cycle is automated, thus removing any clinician variability
and allowing women to be consistently, objectively
screened routinely to assess any NAF changes. The system
is user-friendly, requires minimal training and can be per-
formed by clinical staff. The system is designed for bilat-
eral, simultaneous collection using heat, compression,
and suction combined in a single five minute cycle. Fur-
ther prospective studies with long-term clinical follow-up
are necessary to determine the clinical significance of non-
producers vs. producers, insufficient samples and other
cytologic categories found on NAF samples collected with
the HALO System.
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